Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akela Pharma, a drug development company, has reported a net loss and comprehensive loss of $13.6 million, or $0.63 per share, for the fourth quarter of 2008, compared to a net loss and comprehensive loss of $8.88 million, or $0.75 per share, for the same period of 2007.
Subscribe to our email newsletter
For the full year 2008, the company reported a net loss and comprehensive loss of $25.99 million, or $1.35 per share, compared to a net loss and comprehensive loss of $32.69 million, or $2.79 per share, for the full year 2007.
Akela reported revenues of $3.53 million for the fourth quarter of 2008, compared to $4.70 million for the same period of 2007. For the full year 2008, the company reported revenues of $14.77 million, compared to $12.63 million for the full year 2007.